时间:2021-02-03 14:07:50人气:4712来源: 欧中之声
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
Beidi Festival activities held in Foshan’s Xiqiao Town
(14327)人喜欢2025-04-02Guangxi's Sanyuesan Festival flourishes with culture, song, and romance
(14337)人喜欢2025-04-01Italian delegation explores Guangzhou, strengthening educational and cultural ties
(9040)人喜欢2025-03-31Discover poetic Yunfu in AI-generated Chinese ink brush painting video
(15468)人喜欢2025-03-29Get recharged at Art Week Shenzhen
(9042)人喜欢2025-03-262025 Macao Int’l Parade held to celebrate 26th anniv. of Macao’s Return to Motherland
(15361)人喜欢2025-03-25Hengqin in Lens | Sweat, speed, and smiles: best pics from Hengqin Marathon
(15465)人喜欢2025-03-243.2 km of dreamlike pink vibe in Guangzhou's Haizhu Wetland | MicroInPixels
(13253)人喜欢2025-03-24